Efficacy of an Intervention by Proprioceptive Neuromuscular Facilitation in the Flexibility and Strength of Flexor Muscles and Hamstrings, in Federated Football Players From 18 to 30 Years Old. A Randomized Clinical Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Proprioceptive Disorders
- Sponsor
- Investigación en Hemofilia y Fisioterapia
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Change from baseline flexibility of the hamstring muscles after treatment and at month
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Introduction: The loss of normal values of ROM due to the lack of flexibility and strength in the hip flexors, quadriceps and hamstrings in soccer players can cause a loss of mobility of the hip and knee joint. Proprioceptive neuromuscular facilitation is an active-assisted stretching technique used to improve flexibility and therefore the ranges of joint mobility.
Aim. To assess the effectiveness of an intervention by proprioceptive neuromuscular facilitation in the improvement of flexibility and strength in the hamstring, hip flexor and quadriceps musculature compared to conventional stretches in football players.
Study design. Randomized, multicentric, single-blind clinical study. Methods. The 30 players will be randomly assigned to the study groups: experimental (proprioceptive neuromuscular facilitation and static stretches) and control (static stretches). The treatment will last 6 weeks, with two sessions a week of 5 minutes each. The study variables will be the range of hip mobility (using goniometry), hamstring flexibility (using the EPR test, inclinometer) and the strength of hip flexors, quadriceps and hamstrings (through the RM test). A descriptive statistical analysis will be carried out calculating the main statistical characteristics and after calculating the normality of the sample (test Kolmogorov- Smirnov), the differences between evaluations in each group (t-student test) and the intra- and intersubject effect will be calculated (ANOVA of repeated measures).
Expected results. Improved hip mobility, hamstring flexibility and strength in hip flexors, quadriceps and hamstrings muscles.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Volleyball players
- •From 18 to 30 years old
- •Federated in the Royal Federation of Football of the Community of Madrid
- •Not had any musculoskeletal injuries in the last 3 months.
Exclusion Criteria
- •Impossibility, for work or academic reasons, to comply with the requirements of the study (interventions and evaluations);
- •Under pharmacological treatment
- •Who are exercising a physiotherapy treatment parallel to the development of the study
- •Not sign the informed consent document.
Outcomes
Primary Outcomes
Change from baseline flexibility of the hamstring muscles after treatment and at month
Time Frame: Screening visit, within the first seven days after treatment and after one month follow-up visit
The measurement instrument to measure the flexibility of the hamstring muscles is the passive elevation of the straight leg with an inclinometer (model ISOMED, Inc., Portland, OR) to be placed on the tibia (as distal as possible). The physiotherapist will maintain the extension of the knee and the leg will be lifted by the evaluator to a hip flexion, until the subject indicates pain in the hamstring muscles, when the evaluator perceives hip flexion restriction or when a posterior pelvic tilt occurs. The contralateral knee of the subject will remain in extension. The unit of measurement of the test is the maximum angle read from the inclinometer at the point of maximum flexibility, in degrees, with the normative range of 75 to 80 degrees (the greater the degree of flexibility, the greater the flexibility).
Secondary Outcomes
- Change from baseline the range of motion of hip after treatment and at month(Screening visit, within the first seven days after treatment and after one month follow-up visit)
- Change from baseline strength of upper limbs after treatment and at month(Screening visit, within the first seven days after treatment and after one month follow-up visit)